Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
Sponsor: Exystat
This PHASE3 trial investigates Patients With Non-Small Cell Lung Cancer and is currently actively recruiting participants. Exystat leads this study, which shows 12 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Exystat
- Genome Diagnostics (GenDx)
- OSE Immunotherapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Aberdeen, United Kingdom , Athens, Greece , Avignon, France , Babylon, United States , Badalona, Spain , Baltimore, United States , Barakaldo, Spain , Barcelona, Spain and 159 more locations